Braskem is considering expanding its ethylene cracker and polyethylene complex in the Brazilian state of Rio de Janeiro by 220,000 metric tons per year. During a call with analysts, company officials ...

"We are excited to be entering into this collaboration with Synfini to accelerate drug discovery around a publicly available high-value target,” said Helena Mancebo, CEO of Multispan. "By using ...

Tectonic Therapeutic, Inc. (NASDAQ: TECX) has announced the complete results from part A of the phase 1b clinical trial of ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes, and other metabolic diseases.

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Taste, pain, or response to stress—nearly all essential functions in the human body are regulated by molecular switches ...

Prostaglandin E2 (PGE2), a bioactive lipid derived from arachidonic acid, mediates a broad range of physiological processes ...

Hepatocellular carcinoma (HCC), which accounts for up to 80% of cases of primary liver cancer, is typically diagnosed in an advanced stage, meaning a poor prognosis. Understanding what drives ...

SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today ...

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...